— Know what they know.
Not Investment Advice
Also trades as: EW.SW (SIX)

EW NYSE

Edwards Lifesciences Corporation
1W: +2.9% 1M: +4.6% 3M: +5.9% YTD: +6.4% 1Y: +19.3% 3Y: +30.7% 5Y: -21.0%
$90.82
+0.26 (+0.29%)
After Hours: $87.25 (-3.57, -3.93%)
Weekly Expected Move ±3.2%
$83 $86 $89 $92 $95
NYSE · Healthcare · Medical - Devices · Tech Score Buy · Power 70 · $52.3B mcap · 569M float · 0.692% daily turnover · Short 45% of daily vol
Credit Risk of going bust: lower than 96% of companies Debt: 1.3% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.06 (down 99.9%), Edwards Lifesciences Corporation would be worth roughly what it owes.
Total debt $704.4M against a stock market value of $52.20B.
Distance to default 20.45 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $299.4M (short-term plus half of long-term), stock volatility 25.5%; Altman Z 12.73. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

Balance Sheet Trends

Total Assets
$13.7B +4.9% ▲
5Y CAGR: +13.6%
Total Liabilities
$3.4B +12.3% ▲
5Y CAGR: +4.8%
Shareholders Equity
$10.3B +3.4% ▲
5Y CAGR: +17.7%
Cash & Investments
$4.2B +6.3% ▲
5Y CAGR: +24.7%
Total Debt
$705M +0.8% ▲
5Y CAGR: +0.3%
Net Debt
-$2.2B +4.8% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$863M$769M$1.1B$3.0B$2.9B
Short-Term Investments$604M$446M$500M$931M$1.3B
Cash & ST Investments$1.5B$1.2B$1.6B$4.0B$4.2B
Net Receivables$665M$699M$828M$727M$912M
Inventory$727M$876M$904M$1.1B$1.1B
Other Current Assets$237M$196M$542M$374M$339M
Total Current Assets$3.2B$3.1B$4.0B$6.3B$6.7B
Property, Plant & Equip.$1.6B$1.7B$1.7B$1.8B$1.9B
Goodwill & Intangibles$1.5B$1.4B$1.5B$3.0B$2.9B
Long-Term Investments$1.8B$1.2B$584M$308M$774M
Other Non-Current Assets$111M$299M$774M$732M$235M
Total Non-Current Assets$5.3B$5.2B$5.3B$6.8B$7.0B
Total Assets$8.5B$8.3B$9.4B$13.1B$13.7B
— Liabilities —
Accounts Payable$204M$202M$187M$197M$228M
Short-Term Debt$0$0$0$0$24M
Deferred Revenue$0$0$0$54M$27M
Other Current Liabilities$343M$305M$530M$443M$874M
Total Current Liabilities$1.0B$1.0B$1.2B$1.5B$1.8B
Long-Term Debt$596M$596M$597M$598M$598M
Other Non-Current Liab.$970M$798M$786M$811M$865M
Total Non-Current Liabilities$1.6B$1.5B$1.4B$1.5B$1.5B
Total Liabilities$2.7B$2.5B$2.6B$3.0B$3.4B
— Equity —
Common Stock$642M$646M$650M$655M$659M
Retained Earnings$6.1B$7.6B$9.0B$13.2B$14.2B
Accumulated OCI-$158M-$255M-$243M-$244M-$238M
Total Stockholders Equity$5.8B$5.8B$6.7B$10.0B$10.3B
Total Liabilities & Equity$8.5B$8.3B$9.4B$13.1B$13.7B
— Key Metrics —
Total Debt$690M$691M$685M$700M$705M
Net Debt-$172M-$78M-$447M-$2.3B-$2.2B
Total Investments$2.4B$1.7B$1.1B$1.2B$2.1B

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms